

FORM 5

QUARTERLY LISTING STATEMENT

Name of Listed Issuer: Albert Labs International Corp. (the "Issuer").

Trading Symbol: ABRT

This Quarterly Listing Statement must be posted on or before the day on which the Issuer's unaudited interim financial statements are to be filed under the *Securities Act*, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer's first, second and third fiscal quarters. This statement is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the Exchange website.

General Instructions

- (a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Listed Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

There are three schedules which must be attached to this report as follows:

SCHEDULE A: FINANCIAL STATEMENTS

Financial statements are required as follows:

For the first, second and third financial quarters interim financial statements prepared in accordance with the requirements under Ontario securities law must be attached.

If the Issuer is exempt from filing certain interim financial statements, give the date of the exempting order.

See Attached as Schedule A the Interim Financial Statements for period ending September 30, 2023

SCHEDULE B: SUPPLEMENTARY INFORMATION

The supplementary information set out below must be provided when not included in Schedule A.

1. Related party transactions

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

- (a) A description of the relationship between the transacting parties. Be as precise as possible in this description of the relationship. Terms such as affiliate, associate or related company without further clarifying details are not sufficient.
- (b) A description of the transaction(s), including those for which no amount has been recorded.
- (c) The recorded amount of the transactions classified by financial statement category.
- (d) The amounts due to or from Related Persons and the terms and conditions relating thereto.
- (e) Contractual obligations with Related Persons, separate from other contractual obligations.
- (f) Contingencies involving Related Persons, separate from other contingencies.

All related party transactions have been disclosed in the Issuer's financial statements and MD&A for the interim period ended September, 2023.

2. Summary of securities issued and options granted during the period.

Provide the following information for the period beginning on the date of the last Listing Statement (Form 2A):

- (a) summary of securities issued during the period,

Date of Issue	Type of Security (common shares, convertible debentures, etc.)	Type of Issue (private placement, public offering, exercise of warrants, etc.)	Number	Price	Total Proceeds	Type of Consideration (cash, property, etc.)	Describe relationship of Person with Issuer (indicate if Related Person)	Commission Paid
N/A								

(b) summary of options granted during the period,

Date	Number	Name of Optionee if Related Person and relationship	Generic description of other Optionees	Exercise Price	Expiry Date	Market Price on date of Grant
N/A						

3. Summary of securities as at the end of the reporting period.

Provide the following information in tabular format as at the end of the reporting period:

- (a) description of authorized share capital including number of shares for each class, dividend rates on preferred shares and whether or not cumulative, redemption and conversion provisions,
Authorized share capital: An unlimited number of common shares without par value
- (b) number and recorded value for shares issued and outstanding,
As of September 30, 2023, there were 74,413,267 Common Shares issued and outstanding as fully paid and non-assessable shares.
- (c) description of options, warrants and convertible securities outstanding, including number or amount, exercise or conversion price and expiry date, and any recorded value, and
As of September 30, 2023, there were 5,735,000 options to purchase common shares at a price of \$0.10 per share, and share purchase

warrants to purchase 6,250,000 common shares and a price of \$0.07 per share for 24 months from issuance.

- (d) number of shares in each class of shares subject to escrow or pooling agreements or any other re
- (e) striction on transfer.

Nil

- 4. List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.**

Name	Position
Chand Jagpal	CEO and Director
Rob Kang	Director
Dr. Shabir Hasham	Director
Katie Shelton-Innes	Director

SCHEDULE C: MANAGEMENT DISCUSSION AND ANALYSIS

Provide Interim MD&A if required by applicable securities legislation.

See attached as Schedule C the Interim MD&A for the period ended September 30, 2023

Certificate Of Compliance

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.
- 2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
- 4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated December 5, 2023.

Chand Jagpal
Name of Director or Senior Officer


Signature

CFO
Official Capacity

Issuer Details Name of Issuer Albert Labs International Corp.	For Quarter Ended September 30, 2023	Date of Report YY/MM/D 05/12/2023
Issuer Address #201- 6996 Merritt Avenue, Burnaby, BC		
City/Province/Postal Code British Columbia	Issuer Fax No. ()	Issuer Telephone No. ()
Contact Name Chand Jagpal	Contact Position CFO	Contact Telephone No. +44 7828 008237
Contact Email Address chand@albertlabs.com	Web Site Address www.albertlabs.com	

SCHEDULE A

**Albert Labs International Corp.
(Formerly ME Resources Corp.)**

**Condensed Consolidated
Interim Financial Statements**

Three and Nine Months Ended September 30, 2023 and 2022

(Unaudited - Expressed in Canadian Dollars)

NOTICE TO READER

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim financial statements of the Company have been prepared by and are the responsibility of the Company's management. The unaudited condensed interim financial statements have been prepared using accounting policies in compliance with International Financial Reporting Standards for the preparation of the condensed interim financial statements and are in accordance with IAS 34 – *Interim Financial Reporting*.

The Company's independent auditor has not performed a review of these unaudited condensed interim financial statements in accordance with standards established by the Canadian Chartered Professional Accountants for a review of the interim financial statements by an entity's auditor.

Albert Labs International Corp. (Formerly ME Resources Corp.)
Condensed Consolidated Interim Statements of Financial Position
(Unaudited - Expressed in Canadian Dollars)

	September 30, 2023	December 31, 2022
	\$	\$
ASSETS		
Current assets		
Cash	111	79,122
Note receivable (Note 5)	12,720	12,360
	12,720	91,482
Non-current assets		
Equipment and furniture (Note 7)	51,794	72,277
Total assets	64,625	163,759
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities (Note 6)	337,568	369,076
Due to related parties (Note 8)	160,000	160,000
Loan payable (Note 11)	10,130	
	507,698	529,076
SHAREHOLDERS' DEFICIENCY		
Share capital (Note 4)	8,075,506	7,856,756
Subscription received	46,400	106,000
Reserves	1,398,080	1,074,026
Accumulated other comprehensive loss	(30,981)	(31,148)
Deficit	(9,932,078)	(9,370,951)
	(443,073)	(365,317)
Total shareholders' deficiency and liabilities	64,625	163,759

Note 1: Nature and operation and going concern

Authorized for issuance by the Board of Directors on November 28, 2023

/s/Dr. Shabir Hasham

Director

/s/Chand Jagpal

Director

See accompanying notes to the condensed consolidated interim financial statements

Albert Labs International Corp. (Formerly ME Resources Corp.)
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss
(Unaudited - Expressed in Canadian Dollars)

	Three months ended September 30,		Nine months ended September 30,	
	2023	2022	2023	2022
	\$	\$	\$	\$
Expenses				
Amortization	6,828	2,322	20,483	6,965
Consulting and management	-	344,348	60,416	1,039,886
General and administration	3,319	32,729	22,319	108,786
Listing expenditures	-	3,176	-	2,933,453
Promotion and advertisement	-	9,052	41,204	119,568
Professional fees	4,988	10,566	16,298	152,838
Research	-	41,279	110,621	737,070
Salaries and wages	1,478	67,176	31,934	158,734
Share-based compensation	-	-	242,804	-
Travel	83	25,097	14,898	55,121
Operating Loss	(16,696)	(535,745)	(560,977)	(5,312,421)
Other Items				
Interest Expense	(150)	-	(150)	-
Net loss	(16,846)	(535,745)	(561,127)	(5,312,421)
Other comprehensive loss	-	(5,626)	167	(46,481)
Comprehensive Loss	(16,846)	(541,371)	(560,960)	(5,358,902)
loss per share – basic and diluted	(0.00)	(0.01)	(0.01)	(0.09)
Weighted average number of outstanding common shares, basic and diluted	74,413,267	68,163,267	73,255,860	61,715,459

See accompanying notes to the condensed consolidated interim financial statements

	Number of shares	Amount \$	Subscription received \$	Warrant reserve \$	Option reserve \$	Accumulated other comprehensive loss \$	Deficit \$	Total \$
Balance, December 31, 2021	43,055,398	1,791,575	18,037	-	-	-	(2,312,138)	(502,526)
Shares issued for subscription received in 2021	71,468	17,867	(18,037)	-	-	170	-	-
Shares issued for cash, net of finder's fees of \$211,787 (Note 4)	6,540,927	1,423,445	-	-	-	-	-	1,423,445
Shares issued for debt settlement (Note 4)	8,826,740	2,206,685	-	-	-	-	-	2,206,685
Share issuance to shareholders of MEC (Note 1)	6,367,192	1,591,798	-	-	-	-	-	1,591,798
Share issuance to creditors of MEC (Note 1)	3,301,542	825,386	-	-	-	-	-	825,386
Subscription received	-	-	106,000	-	-	-	-	106,000
Share-based compensation	-	-	-	-	1,074,026	-	-	1,074,026
Translation of subsidiary	-	-	-	-	-	(31,318)	-	(31,318)
Loss for the year	-	-	-	-	-	-	(7,058,813)	(7,058,813)
Balance, December 31, 2022	68,163,267	7,856,756	106,000	-	1,074,026	(31,148)	(9,370,951)	(365,317)
Shares issued for subscription received in 2022	1,241,666	43,458	(59,600)	16,142	-	-	-	-
Shares issued for cash	5,008,334	175,292	-	65,108	-	-	-	240,400
Share-based compensation	-	-	-	-	242,804	-	-	242,804
Translation of subsidiary	-	-	-	-	-	167	-	167
Loss for the period	-	-	-	-	-	-	(561,127)	(561,127)
Balance, June 30, 2023	74,413,267	8,075,506	46,400	81,250	1,316,830	(30,981)	(9,932,078)	(443,073)

See accompanying notes to the condensed consolidated interim financial statements

Albert Labs International Corp. (Formerly ME Resources Corp.)
Condensed Consolidated Interim Statements of Cash Flows
(Unaudited - Expressed in Canadian Dollars)

Nine months ended September 30,	2023	2022
	\$	\$
OPERATING ACTIVITIES		
Loss for the period	(561,127)	(5,312,421)
Items not involve cash		
Amortization	20,483	6,965
Fees paid by issuance of shares	-	1,781,245
non-cash listing expenses	-	2,545,505
Interest income	(360)	-
Share-based compensation	242,804	-
Interest expense	150	-
Changes in non-cash working capital items:		
- accounts payable and accrued liabilities	(31,508)	(280,990)
- prepaid	-	10,000
Cash used in operating activities	(329,558)	(1,249,696)
Cash flows from financing activities		
Proceeds from shares issuance, net of finder's fees	240,400	1,421,292
Proceeds from loan payable	9,980	-
Cash provided by financing activities	250,380	1,421,292
Cash flows from investing activities		
Acquisition of equipment	-	(70,333)
Issuance of promissory note	-	(12,000)
Payment of prepayment for leasehold improvement	-	(14,013)
Cash used in investing activities	-	(96,346)
Effect of foreign exchange on cash on hands	167	(46,481)
Net cash inflow (outflow)	(79,011)	28,769
Cash, beginning of period	79,122	76,697
Cash, end of period	111	105,466

See accompanying notes to the condensed consolidated interim financial statements

Albert Labs International Corp. (Formerly ME Resources Corp.)

Notes to the Condensed Consolidated Interim Financial Statements

Three and Nine Months Ended September 30, 2023 and 2022

(Unaudited - Expressed in Canadian Dollars)

1. NATURE AND CONTINUANCE OF OPERATIONS

Business Combination

The accompanying consolidated financial statements have been prepared after giving effect to the reverse takeover ("RTO") of ME Resources Corp. ("MEC") by Albert Labs Inc. ("AL") which was completed on March 10, 2022, whereby MEC has acquired AL as its wholly owned subsidiary. As the shareholders of AL acquired control of the combined entity, AL is considered the accounting acquirer of the RTO and AL is considered the accounting parent of MEC.

MEC was incorporated under the Business Corporation Act (British Columbia) on October 16, 2009. Before the Completion of the RTO, MEC's shares commenced trading on the Canadian Securities Exchange ("CSE") under the symbol MEC.

Albert Labs Inc., ("AL") was incorporated under the Business Corporation Act (British Columbia) on September 16, 2020. The Company's head and registered office address is 201-6996 Merritt Avenue, Burnaby, BC, V5J 4R6.

MEC has changed its name to Albert Labs International Corp. ("AL Intl" or the "Company") upon the completion of the RTO. The Company's shares commenced trading on the CSE under the name ABRT commencing March 10, 2022.

At the date of acquisition, MEC did not meet the definition of a business and, accordingly, the transaction has been accounted for as an acquisition of assets by AL. The acquisition is accounted for in accordance with IFRS 2 *Share Based Payments* and IFRS 3 *Business Combination* ("IFRS 3"). MEC did not qualify as a business as defined in IFRS 3 as there were no substantive processes in place. The net assets and liabilities of MEC have been measured at their fair value on the acquisition date with the allocation of proceeds as follow:

Proceeds of acquisition	\$
Fair value of 6,367,192 common shares of AL issued to MEC's shareholders (Note 4)	1,591,798
Fair value of 3,301,542 common shares of AL issued to MEC's creditors for debt settlement (Note 4)	825,386
Assumption of accounts payable and due to related parties of MEC	1,325,612
Gain from debt settlement with creditors of MEC (Note 4)	(825,356)
Listing expenses	2,917,440

As the fair value of tangible and intangible assets held by MEC was \$Nil when the RTO was completed, the whole amount of proceeds of acquisition has been expensed as listing expenditures for the Company to list its common shares on the CSE.

The Company's principal line of business is to research and develop drugs to ensure accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs.

Going Concern

These consolidated financial statements have been prepared using International Financial Reporting Standards applicable to a going concern, which assume that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. Different bases of measurement may be appropriate if the Company is not expected to continue operations for the foreseeable future. The Company's continuation as a going concern is dependent whether the Company can develop an economically viable business, and generate funds there from and/or raise equity capital to meet current and future obligations. The Company has not yet achieved profitable operations and expects to incur further losses in the development of its business. These factors indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.

Should the Company be unable to continue as going concern, the net realizable value of its assets may be materially less than the amounts on its statements of financial position.

Albert Labs International Corp. (Formerly ME Resources Corp.)

Notes to the Condensed Consolidated Interim Financial Statements

Three and Nine Months Ended September 30, 2023 and 2022

(Unaudited - Expressed in Canadian Dollars)

2. BASIS OF PRESENTATION

Statement of compliance

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standards (“IAS”) 34 *Interim Financial Reporting* and should be read in conjunction with the annual financial statements for the year ended December 31, 2022, which have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and Interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”).

These condensed consolidated interim financial statements were authorized for issue by the Board of Directors on November 28, 2023.

Basis of Preparation

These condensed consolidated interim financial statements have been prepared on a historical cost basis, except for certain financial instruments carried at fair value. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

These condensed consolidated interim financial statements incorporate the accounts of the Company and its wholly owned subsidiaries, Albert Labs UK Ltd., a company incorporated in the United Kingdom. A subsidiary is an entity in which the Company has control, where control requires exposure or rights to variable returns and the ability to affect those returns through power over the investees. All intercompany transactions and balances have been eliminated on consolidation.

3. SIGNIFICANT ACCOUNTING POLICIES

The Company has not adopted new accounting policies since its recent year ended December 31, 2022.

The preparation of financial statements in accordance with IFRS requires the Company to make estimates and assumptions concerning the future. The Company’s management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. Estimates and assumptions where there is significant risk of material adjustments to assets and liabilities in future accounting periods include the fair value measurements for financial instruments and the recognition and measurement of deferred tax assets.

The preparation of financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgment in applying the Company’s financial statements include:

- the classification of financial instruments;
- the assessment of the Company’s ability to continue as a going concern; and
- the determination of the recoverability of the Company’s deferred tax assets
- share-based payments and compensation

4. SHARE CAPITAL

a) Share capital

Authorized share capital: An unlimited number of common shares without par value.

Share consolidation: On March 10, 2022, the company completed a consolidation of its common shares on the basis of one post-consolidated share for every 10 pre-consolidated shares. All references to share and per share amounts in these financial statements have been retroactively restated to reflect the share consolidation.

Albert Labs International Corp. (Formerly ME Resources Corp.)

Notes to the Condensed Consolidated Interim Financial Statements

Three and Nine Months Ended September 30, 2023 and 2022

(Unaudited - Expressed in Canadian Dollars)

5. SHARE CAPITAL (CONTINUED)

a) Share capital (continued)

Issued and outstanding:

2023

On February 22, 2023 the Company closed a non-brokered private placement for the issuance of 6,250,000 security units ("Unit") at a price of \$0.048 per Unit. Each Unit is comprised of one common share of Albert Labs and one non-transferable Common Share purchase warrant. Each warrant is exercisable to one common share of Albert Labs at an exercise price of \$0.07 for 24 months from issuance. In connection with this private placement, the Company applied \$59,600 from the \$106,000 subscription received in 2022 and received cash of \$240,400, totalling \$300,000.

During the period ended September 30, 2023, the Company initiated a non-brokered private placement for gross proceeds of up to \$3,000,000 (the "**Private Placement**"), at a price of \$0.08 per Unit (the "**Units**"). Each Unit is comprised of one common share of Albert Labs (the "**Common Share**") and one half of one non-transferable Common Share purchase warrant (the "**Warrant**"). Each full Warrant will be exercisable to acquire one common share of Albert Labs at an exercise price of \$0.12 for 12 months from the date of the closing of the Private Placement. As of the date of this report, this Private Placement was not completed.

2022

Following common shares of the Company were issued:

- Issuance of 8,826,740 common shares at \$0.25 per shares to settle accounts payable and for services rendered.
- Issuance of 6,540,927 common shares pursuant to a private placement at \$0.25 per share for cash with \$211,787 finder's fees paid.
- Issuance of 6,367,192 common shares to shareholders of MEC at \$0.25 per share in exchange for 6,367,192 common shares of MEC (Note 1) in connection with the RTO.
- Issuance of 3,301,542 common shares to creditors of MEC at \$0.25 per share (totalling \$825,356) for debt settlement of \$1,650,712. The Company recorded a gain of settlement of \$825,356 which was recorded as a reduction of the listing expenses (Note 1).
- Issuance of 71,468 common shares at \$0.25 per share to account for share subscription of \$18,037 received in 2021.

b) Stock option

The Company has a stock option plan under which employees, directors, and key consultants and/or advisors are eligible to be granted options. Under the stock option plan, which was approved by the shareholders, the maximum number of outstanding stock options under the plan is 10% of the number of the common shares outstanding. The number of stock options and the exercise price is set by the Company's Board of Directors based on the market value at the time of granting.

2023

There were no options granted, exercised, or cancelled

2022

On October 21 2022, the Company granted 5,325,000 stock options to the Company's directors and officers. These options have a five-year term, with an exercise price of \$0.10 per share, whereby 20% of these options vested at the grant date and at each of four consecutive anniversary thereafter.

On October 31, 2022, the Company granted 410,000 stock options to a consulting firm. These options have a two-year term, with an exercise price of \$0.25 per share, whereby 100% of these options vested at the grant date.

Albert Labs International Corp. (Formerly ME Resources Corp.)

Notes to the Condensed Consolidated Interim Financial Statements

Three and Nine Months Ended September 30, 2023 and 2022

(Unaudited - Expressed in Canadian Dollars)

4. SHARE CAPITAL (CONTINUED)

b) Stock option (continued)

Continuity is as follows:

	Number.	Exercise Price	Expiry date
Balance, December 31, 2021	-	N/A	N/A
Stock options, issued October 20, 2022	5,325,000	\$0.10	20, Oct, 2027
Stock options, issued October 20, 2022	410,000	\$0.25	20, Oct, 2024
Balance December 31, 2022 and September 30, 2023	5,735,000	\$0.11	
Options exercisable, December 31, 2022 and September 30, 2023	1,475,000	\$0.14	

As at September 30, 2023, the weighted average exercise price of the outstanding stock options is \$0.11 per share (2022/12/31 – \$0.11) with a remaining life of 3.84 years (2022/12/31 – 4.59 years).

The fair value of the options were determined by using Black-Scholes option pricing model with the following assumptions:

	2023	2022
Expected volatility	100%	100%
Expected life	2-5 years	2-5 years
Risk-free interest rate	3.84%-4.28%	3.84%-4.28%
Expected forfeiture rate	0%	0%
Expected dividend	-	-

During the nine months ended September 30, 2023, the Company recorded share-based compensation of \$242,804 (2022 - \$Nil)

c) Share purchase warrants

Continuity is as follows:

	Number.	Exercise Price	Expiry date
Balance, December 31, 2021 and 2022	-	N/A	N/A
Issuance (Note 4 (a))	6,250,000	\$0.07	Feb 22, 2025
Balance September 30, 2023	6,250,000	\$0.07	Feb 22, 2025

As at September 30, 2023, the weighted average exercise price of the outstanding share purchase warrant is \$0.07 per share (2022/12/31 – N/A) with a remaining life of 1.60 years (2022/12/31 – N/A).

5. NOTE RECEIVABLE

As at September 30, 2023, the Company's note receivable comprised solely of a promissory note advance to an arm's length entity with a carrying value of \$12,720 (2022/12/31 - \$12,360). This unsecured promissory note has a principal of \$12,000, is payable on demand, and has an interest rate of 6% per annum.

Albert Labs International Corp. (Formerly ME Resources Corp.)

Notes to the Condensed Consolidated Interim Financial Statements

Three and Nine Months Ended September 30, 2023 and 2022

(Unaudited - Expressed in Canadian Dollars)

6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	September 30, 2023	December 31, 2022
	\$	\$
Trade payables	209,852	209,853
Accrued liabilities	127,716	159,223
	337,568	369,076

7. PROPERTY AND EQUIPMENT

	Research equipment	Equipment and furniture	Total
	\$	\$	\$
Cost:			
December 31, 2021	-	13,424	13,424
addition	75,634	-	75,634
September 30, 2023 and December 31, 2022	75,634	13,424	89,058
Accumulated amortization			
December 31, 2021	-	2,014	2,014
addition	11,345	3,422	14,767
December 31, 2022	11,345	5,436	16,781
addition	17,018	3,465	20,483
September 30, 2023	28,363	8,901	37,264
Net:			
December 31, 2022	64,289	7,988	72,277
September 30, 2023	47,271	4,523	51,794

8. RELATED PARTY TRANSACTIONS

a) Transactions with key management personnel and directors were as follows:

Nine months ended September 30,	2023	2022
	\$	\$
Consulting fees	-	422,200
Share-based compensation	150,470	-

During the year ended December 31, 2022, an amount of \$586,590 of consulting fees charged by related parties have been settled by Company's common shares at \$0.25 per share. The Company also issued common shares at \$0.25 per share to settle the amount of \$395,000 accounts payable for unpaid consulting fees charged in 2021 (Note 4).

During the year ended December 31, 2022, the director and CFO assigned \$125,000 in accounts payable to a non-related party; and pursuant to a Debt Settlement Agreement dated March 11, 2022, the debt was settled by issuance of 250,000 of common shares at a deemed price \$0.50 per share. A gain on settlement on the issuance of shares of \$0.25 per common share was recognized as a reduction of the listing expenses.

Albert Labs International Corp. (Formerly ME Resources Corp.)

Notes to the Condensed Consolidated Interim Financial Statements

Three and Nine Months Ended September 30, 2023 and 2022

(Unaudited - Expressed in Canadian Dollars)

8. RELATED PARTY TRANSACTIONS (CONTINUED)

b) Balances due to related parties:

Amounts due to related parties are unsecured, non-interest bearing and have no fixed terms of repayment.

Due to Related parties	September 30, 2023	December 31, 2022
	\$	\$
Director and CEO	10,000	10,000
Director and CFO	60,000	60,000
Director	90,000	90,000
	160,000	160,000

9. FINANCIAL INSTRUMENTS**Fair value**

The fair value of the Company's financial assets and liabilities approximate their carrying amount due to their short terms to maturity.

Financial Risk Management

The Company is exposed in varying degrees to a variety of financial instrument related risks.

Credit Risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's exposure to credit risk is on its cash held. The Company's cash is deposited in two banks with high creditworthy.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company has a planning and budgeting process in place to help determine the funds required to support the Company's normal operating requirements on an ongoing basis. The Company ensures that there are sufficient funds to meet its short-term business requirements, taking into account its anticipated cash flows from operations and its holdings of cash. Historically, the Company's sole source of funding has been the issuance of equity securities for cash, primarily through private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding. The Company's liquidity risk as assessed as high.

Interest Rate Risk

Interest rate risk refers to the risk that fair values of future cash flows of a financial instrument will fluctuate due to changes in market interest rates. The Company does not have material financial assets or liabilities that are exposed to fluctuation of interest rate. As a result, the exposure to interest rate risk is not significant.

Currency Risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

The Company is exposed to foreign currency risk to the extent that monetary assets and liabilities held by the Company are not denominated in its functional currency. The Company does not manage currency risk through hedging or other currency management tools.

As at September 30, 2023 and December 31, 2022, the Company's exposure to foreign currency risk on its financial instruments are not material.

Albert Labs International Corp. (Formerly ME Resources Corp.)**Notes to the Condensed Consolidated Interim Financial Statements****Three and Nine Months Ended September 30, 2023 and 2022****(Unaudited - Expressed in Canadian Dollars)**

10. SEGMENT

The Company operates primarily in one business segment: research and development of drugs to ensure accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs.

The Company operates in two areas, Canada and the United Kingdom as of September 30, 2023, a breakdown of the Company's non-current assets and liabilities by area is as follows:

	United Kingdom	Canada	Total
2023/9/30:			
Property and equipment	\$52,944	\$5,678	\$58,622
2022/12/31:			
Property and equipment	\$64,290	\$7,987	\$ 72,277

11. LOAN PAYABLE

On July 6, 2023, the Company received a loan of \$9,980 which bears an interest rate of 6% and is due on demand. During the period ended September 30, 2023, the company recorded interest expense of \$150 in connection to the loan.

Albert Labs International Corp. (Formerly ME Resources Corp.)

Notes to the Condensed Consolidated Interim Financial Statements

Three and Nine Months Ended September 30, 2023 and 2022

(Unaudited - Expressed in Canadian Dollars)

**ALBERT LABS INTERNATIONAL CORP. (FORMERLY ALBERT LABS INC.)
MANAGEMENT'S DISCUSSION AND ANALYSIS
NINE MONTHS ENDED SEPTEMBER 30, 2023**

DATE AND SUBJECT OF REPORT

The following is management's discussion and analysis ("MD&A") in respect of the results of operations and financial position of Albert Labs International Corp. (the "Company" or "Albert Lab") for the nine months ended September 30, 2023. This MD&A should be read in conjunction with the Company's audited consolidated financial statements for the recent year ended December 31, 2022, and with the Company unaudited consolidated interim financial statements for the three and nine months ended September 30, 2023, which are presented in Canadian dollars and prepared in accordance with International Financial Reporting Standards ("IFRS").

The date of this MD&A is November 29, 2023

FORWARD LOOKING STATEMENTS

This MD&A contains statements concerning future results, future performance, intentions, objectives, plans and expectations that are, or may be deemed to be, forward-looking statements. These statements concerning possible or assumed future results of operations of the Company are usually preceded by, followed by or include the words 'believes', 'expects', 'anticipates', 'estimates', 'intends', 'plans', 'forecasts', 'may', 'will', or similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are not guaranteeing of future performance.

These forward-looking statements are based on management's current expectations and involve numerous risks and uncertainties, including, but not limited to, those identified in the Risks & Uncertainties section. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive, and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and while many of which underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate. These factors should be considered carefully, and readers should not place undue reliance on forward-looking statements. The Company reviews its forward-looking statements on an ongoing basis and updates this information when circumstances require it.

COMPANY OVERVIEW & OVERALL PERFORMANCE

Albert Labs Inc., ("AL") was incorporated under the Business Corporation Act (British Columbia) on September 16, 2020. The Company's head and registered office address is 201-6996 Merritt Avenue, Burnaby, BC, V5J 4R6.

On March 10, 2022, AL and ME Resources Corp. ("MEC") completed a share exchange agreement (the "Transaction") whereby AL has become the wholly owned subsidiary of MEC. However, for accounting purposes, the Transaction is considered a reserve-take-over ("RTO") as the shareholders of AL acquired control of MEC. Consequently, AL is considered the accounting acquirer for the RTO.

MEC was incorporated under the Business Corporation Act (British Columbia) on October 16, 2009. Before the Completion of the RTO, MEC's shares commenced trading on the Canadian Securities Exchange ("CSE") under the symbol MEC. MEC's head office is #201 - 6996 Merritt Avenue, Burnaby, BC V5J 4R6, Canada.

MEC changed its name to Albert Labs International Corp. ("AL Intl" or the "Company") upon the completion of the RTO. The Company's shares commenced trading on the CSE under the name ABRT commencing March 10, 2022.

At the date of acquisition, MEC did not meet the definition of a business and, accordingly, the transaction has been accounted for as an acquisition of assets. The acquisition is accounted for in accordance with IFRS 2 Share Based Payments and IFRS 3 Business Combination ("IFRS 3"). MEC did not qualify as a business as defined in IFRS 3 as there were no substantive processes in place. As a result, the RTO is considered as an acquisition of assets. Given the fair value of tangible and intangible

ALBERT LABS INTERNATIONAL CORP. (FORMERLY ALBERT LABS INC.)
MANAGEMENT'S DISCUSSION AND ANALYSIS
NINE MONTHS ENDED SEPTEMBER 30, 2023

assets held by MEC was \$Nil at the acquisition date, the whole amount of proceeds of acquisition has been expensed as listing expenditures for the Company to list its common shares on the CSE. A breakdown of the acquisition proceeds is as follow:

Proceeds of acquisition	\$
Fair value of 6,367,192 common shares of AL issued to MEC's shareholders	1,591,798
Fair value of 3,301,542 common shares of AL issued to MEC's creditors for debt settlement	825,386
Assumption of accounts payable and due to related parties of MEC	1,325,612
Gain from settlement with MEC creditors	(825,356)
Total	2,917,440

As the fair value of tangible and intangible assets held by MEC was \$Nil when the RTO was completed, the whole amount of proceeds of acquisition has been expensed as listing expenditures for the Company to list its common shares on the CSE.

Line of Business

The Company's principal line of business is to research and develop drugs to ensure accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs.

Other Corporate Events

On February 22, 2023, the Company closed a non-brokered private placement for the issuance of 6,250,000 security units ("Unit") at a price of \$0.048 per Unit. Each Unit is comprised of one common share of Albert Labs and one non-transferable Common Share purchase warrant. Each warrant is exercisable to one common share of Albert Labs at an exercise price of \$0.07 for 24 months from issuance. In connection with this private placement, the Company applied \$59,600 from the \$106,000 subscription received in 2022 and received cash of \$240,400, totaling \$300,000.

During the quarter ended June 30, 2023, the Company initiated a non-brokered private placement for gross proceeds of up to \$3,000,000 (the "Private Placement"), at a price of \$0.08 per Unit (the "Units"). Each Unit is comprised of one common share of Albert Labs (the "Common Share") and one half of one non-transferable Common Share purchase warrant (the "Warrant"). Each full Warrant will be exercisable to acquire one common share of Albert Labs at an exercise price of \$0.12 for 12 months from the date of the closing of the Private Placement. As of the date of this report, this Private Placement was not completed.

On July 6, 2023, the Company received a loan of \$9,980 which bears an interest rate of 6% and is due on demand. During the period ended September 30, 2023, the Company recorded interest expense of \$150 in connection to the loan.

On September 5th, 2023, the Company announced the resignation of Michael Raymont as CEO and Director. Chand Jagpal was appointed interim Chief Executive Officer.

SELECTED QUARTERLY INFORMATION

The Company's businesses are not subject to seasonal variations. Following are the Company's quarterly results of the most recent eight quarters:

Three months ended	September 30, 2023	June 30, 2023	March 31, 2023	December 31, 2022
	\$	\$	\$	\$
Total Assets	64,625	71,342	146,197	163,759
Revenue	Nil	Nil	Nil	Nil
Net Loss	(16,846)	(158,388)	(385,893)	(1,746,392)
Loss per share, basic and diluted	(0.00)	(0.01)	(0.01)	(0.03)

ALBERT LABS INTERNATIONAL CORP. (FORMERLY ALBERT LABS INC.)
MANAGEMENT'S DISCUSSION AND ANALYSIS
NINE MONTHS ENDED SEPTEMBER 30, 2023

Three months ended	September 30, 2022	June 30, 2022	March 31, 2022	December 31, 2021
	\$	\$	\$	\$
Total Assets	399,860	1,151,688	1,045,566	163,759
Revenue	Nil	Nil	Nil	Nil
Net Loss	(524,289)	(957,641)	(3,830,491)	(1,235,698)
Loss per share, basic and diluted	(0.01)	(0.01)	(0.08)	(0.03)

RESULTS OF OPERATIONS

Nine months ended September 30,	2023	2022
---------------------------------	------	------

Expenses		
Amortization	20,483	6,965
Consulting and management	60,416	1,039,886
General and administration	22,319	108,786
Listing expenditures (i)	-	2,933,453
Promotion and advertisement	41,204	119,568
Professional fees	16,298	152,838
Research (ii)	110,621	737,070
Salaries and wages	31,934	158,734
Share-based compensation (iii)	242,804	-
Travel	14,898	55,121
Operating Loss	(560,977)	(5,312,421)
Other Items		
Interest Expense	(150)	-
Net loss	(561,127)	(5,312,421)

Three months ended September 30,	2023	2022
----------------------------------	------	------

Expenses		
Amortization	6,828	2,322
Consulting and management	-	344,348
General and administration	3,319	32,729
Listing expenditures (i)	-	3,176
Promotion and advertisement	-	9,052
Professional fees	4,988	10,566
Research (ii)	-	41,279
Salaries and wages	1,478	67,176
Share-based compensation (iii)	-	-
Travel	83	25,097
Operating Loss	(16,846)	(535,745)
Other Items		
Interest Expense	(150)	-
Net loss	(16,846)	(535,745)

(i) The listing expenses (recovery) incurred during 2022 are non-cash and non-recurring which were arising from the RTO.

ALBERT LABS INTERNATIONAL CORP. (FORMERLY ALBERT LABS INC.)
MANAGEMENT'S DISCUSSION AND ANALYSIS
NINE MONTHS ENDED SEPTEMBER 30, 2023

(ii) The amount of research expenditure incurred depends on the financial resources on hands and the progress of research being conducted.

(iii) share-based compensation varies from time to time depending on timing of stock options granted and vesting.

During the nine months ended September 30, 2023, the Company's main assets and liabilities movements are as follows:

- Cash decreased by \$79,011 (2023/9/30: \$111 ; 2022/12/31: \$79,122)

The Company used \$329,558 in its operations which was partially financed by the receipt of \$240,400 from issuance of security units.

LIQUIDITY & CAPITAL RESOURCES

As of September 30, 2023, the Company had a working capital deficiency of \$443,073. In order to finance the Company's operations, the Company has initiated a private placement that will raise up to \$3,000,000.

The Company realizes that the current resources are not adequate for the Company to achieve its long-term objectives. The Company considers different financing options, including, but not limited to, further debt or equity financing, or share for debt settlement, to secure addition financing to provide adequate capital resource for the Company to meet its long-term business objective.

Readers should be cautioned that the Company's continuation as a going concern is dependent whether the Company can develop an economically viable business and generate funds there from and/or raise equity capital to meet current and future obligations. The Company has not yet achieved profitable operations and expects to incur further losses in the development of its business. These factors indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.

The Company is a newly incorporated business and there is no guarantee the Company is able to secure financing as needed.

As of the date of this MD&A, the Company does not have commitments for capital expenditures and the Company is not subject to external requirement in using its capital resources or maintenance of its capital structure.

OFF BALANCE SHEET ARRANGEMENTS

The Company does not have off balance sheet arrangements.

PROPOSED TRANSACTIONS

Other than the proposed private placement disclosed in the above, the Company does not have other proposed transactions that are material to the Company for disclosure.

TRANSACTIONS WITH RELATED PARTIES

a) Transactions with key management personnel and directors were as follows:

Nine months ended September 30,	2023	2022
	\$	\$
Consulting fees	-	22,200
Share-based compensation	150,470	-

ALBERT LABS INTERNATIONAL CORP. (FORMERLY ALBERT LABS INC.)
MANAGEMENT'S DISCUSSION AND ANALYSIS
NINE MONTHS ENDED SEPTEMBER 30, 2023

b) Balances due to related parties:

Amounts due to related parties are unsecured, non-interest bearing and have no fixed terms of repayment.

Due to Related Parties	September 30, 2023	December 31, 2022
	\$	\$
Director and CEO	10,000	10,000
Director and CFO	60,000	60,000
Director	90,000	90,000
	160,000	160,000

OUTSTANDING SHARE DATA

As of the date of this MD&A, the Company has 74,413,267 common shares outstanding and issued.

SIGNIFICANT ACCOUNTING POLICIES, CRITICAL ACCOUNTING ESTIMATES, AND CHANGES

Refer to Note 3 to the Company's interim financial statements for the same period.

FINANCIAL INSTRUMENT RISK EXPOSURE AND RISK MANAGEMENT

Financial Risk Management

The Company is exposed in varying degrees to a variety of financial instrument related risks.

Credit Risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's exposure to credit risk is on its cash held. The Company's cash is deposited in two banks with high creditworthy.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company has a planning and budgeting process in place to help determine the funds required to support the Company's normal operating requirements on an ongoing basis. The Company ensures that there are sufficient funds to meet its short-term business requirements, taking into account its anticipated cash flows from operations and its holdings of cash. Historically, the Company's sole source of funding has been the issuance of equity securities for cash, primarily through private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding.

The Company's liquidity risk as assessed as high.

Currency Risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

The Company is exposed to foreign currency risk to the extent that monetary assets and liabilities held by the Company are not denominated in its functional currency. The Company does not manage currency risk through hedging or other currency management tools.

As at September 30, 2023, and December 31, 2022, the Company's exposure to foreign currency risk on its financial instruments is not material.

ALBERT LABS INTERNATIONAL CORP. (FORMERLY ALBERT LABS INC.)
MANAGEMENT'S DISCUSSION AND ANALYSIS
NINE MONTHS ENDED SEPTEMBER 30, 2023

Interest Rate Risk

Interest rate risk refers to the risk that fair values of future cash flows of a financial instrument will fluctuate due to changes in market interest rates. The Company does not have material financial assets or liabilities that are exposed to fluctuation of interest rate. As a result, the exposure to interest rate risk is not significant.

Classification of financial instruments

Financial instruments included in the statement of financial position are as follows:

	September 30, 2023	December 31, 2022
	\$	\$
Amortized cost:		
Cash	111	79,122
Note receivable	12,720	12,360
Accounts payable accrued liabilities	(337,568)	(369,076)
Due to related parties	(160,000)	(160,000)

Fair value

The Company does not have financial instruments that are measured at their fair values. The financial instruments that are not measured at their fair value have their carrying values approximate their fair values due to their short-term nature.

RISKS AND UNCERTAINTIES

Readers are cautioned that the foregoing lists of risks, uncertainties and other factors are not exhaustive.

Capitalization Risk

It is anticipated that the Company will require additional capital to fully execute its long-term business objectives. There can be no assurance that it will be able to obtain any capital in the future or that attempts to obtain capital in the future will result in terms beneficial to existing investors.

Dilution to the Existing Shareholders

The Company has no other capital resources other than the ability to use its common stock to raise additional capital. The issuance of additional equity securities by the Company could result in a significant dilution in the equity interests of existing shareholders.

Management Risk

The Company's success will largely depend on the capability of its management; management has limited experience in managing the growth of a developing business.

Reliance on Management's Expertise

The Company strongly depends on the business acumen and expertise of its management team and there is little possibility that this dependence will decrease in the near term. The loss of the services of any member of the team could have a material adverse effect on the Company. The Company does not have any key person insurance in place for management.

Profitability Risk

Although the Company will work to become profitable, there can be no assurance that factors beyond its control, such as, but not limited to, successful development of its technology into commercially viable products.

ALBERT LABS INTERNATIONAL CORP. (FORMERLY ALBERT LABS INC.)
MANAGEMENT'S DISCUSSION AND ANALYSIS
NINE MONTHS ENDED SEPTEMBER 30, 2023

Key Personnel Risk

The Company is highly dependent upon the services from external consultants. Loss of these external consultants would adversely affect the achievement of the Company's objectives.

Risks Inherent in the Nature of the Psychopharmacological Industry

Changes in operating costs (including costs for maintenance, insurance), inability to obtain permits required to conduct the Company's business, changes in health care laws and governmental regulations, and various other factors may significantly impact the ability of the Company to generate revenues. Certain significant expenditures, including legal fees, borrowing costs, maintenance costs, insurance costs and related charges, must be made to operate the business, regardless of whether the Company is generating revenue. Government Regulations, Permits and Licenses, the Company's operations may be subject to governmental laws or regulations promulgated by various legislatures or governmental agencies from time to time. A breach of such legislation may result in the imposition of fines and penalties. The cost of compliance with changes in governmental regulations has the potential to reduce the profitability of operations. The Company intends to fully comply with all governmental laws and regulations. The physicians that recommend psychedelic therapy to the Company's patients will be subject to various federal, provincial, and municipal laws in each jurisdiction. If any permits are required for the Company's operations and activities in the future, there can be no assurance that such permits will be obtainable on reasonable terms or on a timely basis, or that applicable laws and regulations will not have an adverse effect on the Company's business. Psilocybin is currently a controlled substance with no medicinal approved use in Canada or the United Kingdom. If a medical use for psilocybin is not developed or if developed, is not approved for use in Canada, the United Kingdom and other jurisdictions, the commercial opportunity that the Resulting Issuer is pursuing may be highly limited. The current and future operations of the Resulting Issuer are and will be governed by laws and regulations governing the health care industry, labour standards, occupational health and safety, land use, environmental protection, and other matters. Amendments to current laws, regulations and permits governing operations and activities of patient therapies, or more stringent implementation thereof, could have a material adverse impact on the Company and cause increases in capital expenditures or costs, or reduction in levels of its business operations.